| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Intraductal papillary mucinous neoplasms (IPMNs) are recognized as one of the risk factors and precursor of pancreatic cancer. To diagnose malignant IPMN before surgery, we conducted gene analysis of resected IPMN by next-generation sequencing and identified TP53 mutation and SMAD4 loss as malignant markers for IPMN. Moreover, we tried to detect these gene alterations with pancreatic juice samples which could be obtained before surgical operation, and we succeeded to detect TP53 mutations in pancreatic juice samples. In the future, we should develop methods to detect these gene alterations with blood samples.
|
